RecruitingPHASE2, PHASE3NCT06862596
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Studying Kennedy disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Masahisa Katsuno
- Principal Investigator
- Masahisa Katsuno, PhD, MD, M.D. Ph.DNagoya University Hospital
- Intervention
- Mexiletine hydrochloride(drug)
- Enrollment
- 68 enrolled
- Eligibility
- 18-80 years · MALE
- Timeline
- 2025 – 2027
Study locations (5)
- Tokyo University Hospital, Bunkyō City, Japan
- Chiba University Hospital, Chiba, Japan
- Hokkaido University Hospital, Sapporo, Japan
- Jichi Medical University Hospital, Shimotsuke, Japan
- Osaka University Hospital, Suita, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06862596 on ClinicalTrials.govOther trials for Kennedy disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07443449International SBMA Project (KDA)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGPHASE2NCT06169046A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular AtrophyGianni Soraru
- RECRUITINGNANCT04944940Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)National Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGNANCT03555578Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"Takeda
- RECRUITINGNCT05966038ALS/MND Natural History Study Data RepositoryMassachusetts General Hospital